This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Uncategorised Disease
  • /
  • ACP-196, a Btk Inhibitor, for Treatment of Novo Ac...
Clinical trial

ACP-196, a Btk Inhibitor, for Treatment of Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma

Read time: 1 mins
Last updated:10th Apr 2014

This study is evaluating two dosing regimens, the safety, and efficacy of a new Bruton tyrosine kinase (Btk) inhibitor, ACP-196, for the treatment of subjects with Relapsed or Refractory de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma.

Category Value
Study start date 2014-04-10

View full details